Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?

Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, was a pioneer in the GLP-1 market. The pharmaceutical giant launched medicines like Ozempic and Wegovy, which became hugely famous and successful brand names.However, Novo Nordisk has been rapidly losing its lead in this area to Eli Lilly (NYSE: LLY), a company with which it's battled in the market for diabetes medicines for decades. Lilly is still recording wins and recently made some clinical progress with a candidate that could grant it an even bigger edge over its competitor. Here's what investors need to know.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool